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Abstract    18 
Acute inhalation studies are conducted in animals as part of chemical hazard identification 19 
and for classification and labelling.  Current methods employ death as an endpoint (OECD 20 
TG403 and TG436) while the recently approved fixed concentration procedure (FCP1) 21 
(OECD TG433) uses fewer animals and replaces lethality as an endpoint with evident 22 
toxicity.  Evident toxicity is the presence of clinical signs that predict that exposure to the 23 
next highest concentration will cause severe toxicity or death in most animals. Approval of 24 
TG433 was the result of an international initiative, led by the National Centre for the 25 
Replacement, Refinement and Reduction of Animals in Research (NC3Rs), which collected 26 
data from six laboratories on clinical signs recorded for inhalation studies on 172 27 
substances. This paper summarises previously published data and describes the additional 28 
analyses of the dataset that were essential for approval of the TG.        29 
 30 
Highlights: 31 
The FCP for acute inhalation toxicity has been accepted by OECD as TG433. 32 
TG433 uses evident toxicity while other approved methods use lethality. 33 
A sighting study with 1 M and 1 F animal reliably identifies the more sensitive sex. 34 
The three methods (LC50, ATC, FCP) showed good agreement in a retrospective analysis.  35 
 36 
Keywords:  37 
                                                          
1
 Abbreviations: FCP, fixed concentration procedure; LC50, concentration causing death in 50% of animals tested; 
GHS, global harmonised system; ATC, acute toxic class; NC3Rs, National Centre for the 3Rs; PPV, positive 
predictive value; Cl; confidence limits; MTD, maximum tolerated dose; TC50; concentration causing toxicity in 
50% of animals tested
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1. Introduction 40 
Acute inhalation studies are conducted in animals as part of chemical hazard identification 41 
and for classification and labelling purposes.  There has been considerable work towards 42 
refining the existing methods so that ‘evident toxicity’ rather than death can be used as an 43 
endpoint, through the use of the fixed concentration procedure (FCP) (OECD, 2004).  This 44 
has recently been accepted as OECD test guideline (TG) 433 as an alternative to the 45 
currently accepted LC502 and the Acute Toxic Class (ATC) methods (OECD TGs 403 and 46 
436 respectively) (OECD, 2009a; OECD, 2009b).  The FCP also has the potential to use 47 
fewer animals, due to the use of a single sex, and fewer studies overall, as it will obviate the 48 
need to test at the next concentration up in some cases. The principles of the three methods 49 
are summarised in Table 1 and are described in more detail in Sewell et al. (2015). In brief, 50 
the LC50 method involves testing at three or more concentrations to enable construction of a 51 
concentration-mortality curve and a point estimation of the LC50 which allows classification 52 
into one of five toxic classes using the globally harmonised system (GHS) of classification 53 
and labelling of chemicals (OECD, 2001) (Table 2).  The ATC method is a refinement of the 54 
LC50.  Rather than a point estimate of the LC50, this method estimates which toxic class the 55 
LC50 falls within, so that classification can be assigned.  It uses an ‘up-and-down’ procedure 56 
to test up to four fixed concentrations from the boundaries of the categories (or toxic classes) 57 
in the GHS classification system.  Depending on the number of deaths at each concentration 58 
further testing may be required, or a classification can be made.  The FCP uses a similar up-59 
and-down approach to the ATC, but instead identifies an exposure concentration that causes 60 
evident toxicity rather than death, so that the LC50 can be inferred (based on the prediction of 61 
death at the next fixed higher concentration).  Classification can then be assigned according 62 
to the GHS criteria using the predicted LC50.  Figures 1, 2 and 3 summarise the possible 63 
study outcomes and the resulting classifications for the LC50, ATC and FCP methods 64 
                                                          
2
 the concentration that is expected to result in the death of 50% of the animals 
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respectively, using a starting concentration of 5mg/L for dusts and mists as an example 65 
(Price et al., 2010).  66 
The FCP was removed from the OECD work plan in 2007 because of three main concerns: 67 
the ill-defined and subjective nature of evident toxicity; the lack of evidence for comparable 68 
performance to the LC50 and ATC methods; and suspected sex differences (the FCP 69 
originally proposed the default use of females).  Concerns about the definition of ‘evident 70 
toxicity’ were raised despite its long use in the Acute Oral Fixed Dose Procedure (OECD 71 
TG420) without guidance on what constitutes evident toxicity, nor in the dermal toxicity 72 
equivalent of this TG (OECD TG434) which was approved in 2017 without similar guidance.   73 
However, all the concerns about the FCP have been resolved through the work of a global 74 
initiative led by the UK National Centre for the Replacement, Refinement and Reduction of 75 
Animals in Research (NC3Rs) resulting in its acceptance in April 2017.   76 
Some of the work that led to this decision has already been published (Sewell et al., 2015). 77 
This previous paper described analyses of a large data set of acute inhalation studies using 78 
the LC50 or ATC methods in which signs predictive of death at the next highest concentration 79 
(i.e. evident toxicity) were identified. Further analyses were needed to address fully the 80 
points noted above and to satisfy concerns raised by the OECD national coordinators during 81 
the consultation process, and were therefore vital for the final acceptance of the FCP 82 
method by OECD. These included further support for the robustness of the signs previously 83 
identified, new statistical calculations to support the value of the sighting study in choosing 84 
the most sensitive sex, and retrospective classifications to compare outcomes obtained 85 
using the three methods. This paper summarises the previously published data and presents 86 
the new analyses that formed the basis for acceptance of the new test guideline.    87 
 88 
2. The robustness of evident toxicity as an endpoint 89 
2.1 Definitions 90 
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Evident toxicity is an accepted endpoint in the fixed dose procedure for acute oral toxicity 91 
studies (OECD TG420) (OECD, 2002a).  Here evident toxicity is defined as “a general term 92 
describing clear signs of toxicity following the administration of test substance, such that at 93 
the next highest fixed dose either severe pain and enduring signs of severe distress, 94 
moribund status or probable mortality in most animals can be expected.”  However, for this 95 
accepted test guideline, no further guidance has been provided on what constitutes ‘evident 96 
toxicity’, and it is not clear how often this test guideline is being used in practice.  97 
Although evident toxicity was already accepted as an endpoint for this existing test guideline, 98 
criticism of this endpoint was a major factor for the withdrawal of the FCP from the OECD 99 
work plan in 2007, due to concerns around subjectivity.  With the aim of making evident 100 
toxicity more objective and transferable between laboratories, the NC3Rs working group 101 
collected data on the clinical signs observed in individual animals during acute inhalation 102 
studies on 172 substances (Sewell et al., 2015).  Because data was collected from a number 103 
of laboratories, there was some variation in terminology, requiring retrospective 104 
harmonisation by the working group leading to an agreed lexicon of signs (Sewell et al., 105 
2015).  These data were analysed to identify signs that could predict lethality would occur if 106 
the animals were exposed to the next highest concentration, lethality here being defined as 107 
the death, or severe toxicity requiring euthanasia, in two or more animals in a group of five. 108 
 109 
There are three important quantities derived from the analysis. The positive predictive value 110 
(PPV) is defined as the percentage of times that the presence of a sign correctly predicts 111 
lethality at the next highest concentration. A value less than 100% indicates some false 112 
positives that would result in over-classification of the substance, undesirable from a 113 
business perspective, but erring on the side of caution for human safety. Sensitivity is 114 
defined as the proportion of lethality predicted by the presence of the sign at the lower 115 
concentration.  There is no expectation that a single sign would predict 100% of toxicity at 116 
the next higher concentration, but signs with very low levels of sensitivity are less useful 117 
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because of their rarity and their small contribution to overall evident toxicity. Less than 100% 118 
sensitivity indicates some false negatives, that is, lethality occurs at the higher concentration 119 
even though the sign was absent at the lower concentration. This does not result in incorrect 120 
classification as testing would be carried out at the higher concentration anyway.  Specificity 121 
is the measure of the percentage of non-lethality at the higher concentration associated with 122 
the absence of the sign at the lower concentration. The individual signs focussed upon were 123 
those with high PPV and specificity, with appreciable sensitivity.  124 
 125 
In the absence of any deaths at the lower concentration, toxicity occurred at the higher 126 
concentration in 77% of the studies (95% CI 72-82%), hence this value was used to set a 127 
threshold for use of a sign as an indicator of toxicity.  Consequently, those signs with PPV’s 128 
not only in excess of this value, but whose lower value of the 95% confidence limits of the 129 
PPV also exceeded 77% were selected. 130 
 131 
2.2 Death as a predictor of toxicity at the next highest concentration 132 
In the Sewell et al. (2015) dataset, death or euthanasia was found in the majority of studies 133 
at one or more concentrations.  The PPV of a single death at the lower concentration was 134 
93% (95% CI 84-98%) i.e. a single death is a strong predictor of lethality at the higher 135 
concentration. Although evident toxicity is the intended endpoint for the FCP method, and 136 
severe toxicity and death are to be avoided where possible, if death does occur this endpoint 137 
can therefore also be used to make decisions concerning classifications (Figure 1). But 138 
interestingly, since death is used as an objective endpoint for LC50 and ATC methods, it 139 
should also be noted that when two deaths occurred at the lower concentration this too was 140 
only 97% (95% CI 91-99%) predictive of lethality at the next higher concentration.  That is to 141 
say, for a small number of the studies conducted, fewer deaths occurred at the higher 142 
concentration than at the lower. For the ATC method in particular, this could lead to an 143 
inaccurate classification.  144 
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 145 
2.3 Signs observed on day 0 146 
 147 
Signs seen on the day of the test cannot unambiguously be ascribed to the chemical and 148 
may have resulted from handling, restraint or the inhalation procedure. Some signs such as 149 
wet coat and writhing were only observed on day 0, but some of the common and severe 150 
signs were seen both on day 0 and on subsequent days. For two such signs, irregular 151 
respiration and hypoactivity, the effect of discounting the day 0 observations increased the 152 
PPV and specificity (Sewell et al., 2015) showing that signs that persist for more than 24h 153 
after exposure are better predictors of toxicity.  However, as pointed out in this paper and in 154 
the new TG, severe signs seen on day 0 should be a signal to halt the study or possibly 155 
euthanize the animals so affected.   156 
 157 
2.4 Signs of evident toxicity 158 
 159 
In the case of one death at the lower concentration, a number of signs observed in the 160 
surviving animals increased the PPV of the single death (Sewell et al., 2015). Some of these 161 
also had high sensitivity. Most importantly, a subset of these were also seen to be highly 162 
predictive in the absence of death at the lower level.  The four signs in this subset were: 163 
hypoactivity, tremors, bodyweight loss (>10%), and irregular respiration (Table 3). The data 164 
showed that if any of these signs were observed in at least one animal from the day after 165 
exposure, animals were highly likely to die if exposed to the next higher concentration.  166 
Where any animals experienced tremors or hypoactivity this was 100% predictive of lethality 167 
at the next higher concentration.  If any animal experienced body weight loss in excess of 168 
10% of their pre-dosing weight, this was predictive of death at the higher concentration in 169 
94% of cases. Similarly, body weight loss has previously been shown to be a reliable and 170 
frequent objective marker for the determination of the maximum tolerated dose (MTD) in 171 
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short term toxicity tests in animals (Chapman et al., 2013).  Irregular respiration was also 172 
highly predictive, being indicative of lethality in 89% of cases. 173 
 174 
These four signs were chosen to represent evident toxicity since they had lower 95% 175 
confidence interval limits in excess of the 77% threshold detailed above.  However, there 176 
were other signs that were also highly predictive of lethality at the next higher concentration, 177 
albeit with wider confidence intervals often due to their infrequent occurrence in the dataset.  178 
For example, oral discharge occurred rarely (sensitivity 2.4%), but was 100% (95% 179 
confidence interval (CI) 54.9 -100%) predictive of lethality at the next highest concentration. 180 
Therefore the signs used to guide the decision of evident toxicity should not necessarily be 181 
restricted to the four signs named in Table 3. Information on the pred                                                                                                                             182 
ictivity and sensitivity of each of the clinical signs observed in the dataset has been made 183 
available in Supplementary Data File 1. Information on subclasses of the dataset for dusts 184 
and mists, males and females is also available. This is intended to complement and add to 185 
study director judgement and experience so that a decision can be made on the recognition 186 
of evident toxicity in the absence of death or the four named signs.  187 
 188 
The definition of ‘evident toxicity’ used for the purpose of the analysis was conservative 189 
when considering the accepted definition of evident toxicity in TG420, since it was based 190 
simply on the prediction of actual mortality or euthanasia at the higher concentration (in the 191 
absence of death at the lower), and did not also include ‘severe distress or moribund status’ 192 
at the higher concentration.  However, this definition was chosen to reflect the different 193 
outcomes used for decision making in the protocol, so that ‘evident toxicity’ could be used to 194 
predict ‘outcome A’ (the death of 2 animals at the higher concentration), and therefore avoid 195 
the need for testing at that level (Figure 1).  By using evident toxicity, classification can be 196 
made based on the prediction of death at the higher concentration.  The method therefore 197 
has the potential to minimise the number of studies (i.e. concentrations tested) that will be 198 
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required to make a classification and reduce the overall degree of suffering of animals in the 199 
study.  200 
 201 
2.5 Severity and duration of signs 202 
Severity of signs was not recorded consistently in the dataset, only whether a sign was 203 
present or not, and as the data had been generated in a number of different laboratories, the 204 
grading of severity may have had a strong subjective element. Therefore in the previous 205 
publication, only the severity of bodyweight loss was examined in more detail as it had been 206 
recorded as either unspecified, mild (reduced weight gain), moderate (10-20% compared 207 
with day 0) or substantial (>20% compared with day 0). In fact, PPV was largely unaffected 208 
by dividing body weight loss into these subcategories, but sensitivity declined because of the 209 
smaller numbers in each category.  210 
Another way of looking at severity was to examine whether the sign was present in more 211 
than one animal. In the previous paper (Sewell et al., 2015), it was shown that for irregular 212 
respiration (the sign for which there are the largest number of observations), the impact on 213 
PPV and specificity of increasing numbers of animals showing the sign was very small.  214 
However, because seeing the sign in a majority of animals was less common, the sensitivity 215 
declined accordingly. 216 
2.6 Combinations and co-occurrence of signs (including signs in isolation) 217 
Sewell et al., (2015) considered whether combinations of signs would increase sensitivity, 218 
and thereby improve prediction of lethality at the higher concentration.  However, the gains 219 
in sensitivity of all pairwise combinations were small because of the strong co-occurrence of 220 
signs, and inclusion of third or fourth signs had progressively less impact.   221 
At the other extreme, we examined whether misclassification was likely if a sign was the only 222 
one reported (i.e. seen in isolation), and occurred only once and in only one animal. Irregular 223 
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respiration and body staining were the most commonly observed signs in isolation (42% and 224 
28% respectively of those animals that showed the sign) (Table 4).  However, of the 268 225 
pairs of studies3 analysed, there were only 5 in which irregular respiration was recorded in 226 
the absence of other signs, and only once in only one animal.  In each case, at least two 227 
animals died at the next higher concentration showing that the single sign was predictive 228 
(Table 5). Admittedly this is a small data set, but the finding supports the general robustness 229 
of the sign which is typically seen in more than one animal, and rarely occurs in isolation.    230 
2.7 Varying concentration ratios 231 
An odd feature of the GHS classification system is that the ratios of LC50 concentrations 232 
defined for each grade 1-5 are not of equal size but vary from 2 to 10.  For example, for 233 
dusts and mists the concentrations tested are 0.05, 0.5, 1.0 and 5.0 mg/l (Table 2). Sewell et 234 
al. (2015) considered how this would affect classifications by the FCP method. It seemed 235 
possible that lethality at the higher concentration would be more likely if the concentration 236 
ratio was larger and that conversely, a smaller change in concentration might lead to a 237 
greater number of false positives i.e. lethality not seen at the higher concentration despite 238 
evident toxicity at the lower. This has now been looked at in two ways. Sewell et al. (2015) 239 
found that, for a small number of signs, the average concentration ratio for false positives 240 
was smaller than for true positives, in agreement with this idea. However, of the four signs 241 
selected as markers of evident toxicity, two were never associated with false positives (PPVs 242 
of 100%) and in the other two cases, the effect of concentration ratio did not reach statistical 243 
significance.  244 
A further analysis was undertaken to look at the effect of the ratio of the higher to lower 245 
concentration on the PPV.  In Table 6, PPVs are shown for a number of signs with >2 to <5, 246 
>5 to <10 or >10-fold ratios between the lower and higher concentrations.  As anticipated, 247 
PPVs are higher for the larger concentration ratios, but since the majority of the studies used 248 
                                                          
3
 A pair of studies indicates a set of data from five animals, either all male or all female, exposed at two 
concentrations differing by at least a factor of two and in which no deaths occurred at the lower concentration. 
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the >2 to <5 fold ratio, the lower numbers in the remaining studies resulted in wider 95% 249 
confidence limits of the PPV values. The conclusion is that the main signs of evident toxicity 250 
were equally predictive regardless of the ratio of the higher to lower concentration.  251 
3. Default sex and sighting studies 252 
For the LC50 procedure, since males and females are treated identically and classifications 253 
are based on the sex that is most sensitive, sex differences generally do not have any 254 
impact on classification. For the ATC procedure, since males and females are not treated 255 
separately and the endpoints are based on the total number of deaths, irrespective of sex, 256 
differences in sensitivity have more of an impact and make the test less stringent. For 257 
example, where there is a 10-fold difference in sex sensitivity, simulations (Price et al., 2011) 258 
showed that substances where the LC50 value of the most sensitive sex falls within GHS 259 
class 3 (the narrowest GHS classification band), these are almost always incorrectly 260 
classified as GHS class 4 (i.e. as less toxic). However, the guideline suggests that testing 261 
should be conducted in the more sensitive sex alone if a sex difference is indicated, which 262 
may mitigate this if sex differences are correctly identified in practice.  263 
The original FCP method proposed the use of females as the default, as these were thought 264 
to be the more sensitive sex, and males only used if they were known to be more sensitive.  265 
In practice, significant differences in sensitivities between the sexes are fairly uncommon.  266 
Price et al., (2011) showed a significant statistical difference between the LC50 values of 267 
males and females for 16 out of 56 substances examined (29%), females being the more 268 
sensitive in 11 of these. The dataset in Sewell et al. (2015) revealed little difference in 269 
sensitivity between the sexes.  There was no difference in the prevalence of death or 270 
animals requiring euthanasia between the sexes, though some clinical signs were more 271 
prevalent in one sex than the other (ano-genital staining was more prevalent in females than 272 
males (p = 0.0002), whereas facial staining and gasping were marginally more common in 273 
males (p = 0.028 and 0.044 respectively). However, the predictivity of these signs did not 274 
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differ between males and females, but the smaller numbers of studies in this analysis led to 275 
wider confidence intervals. 276 
 277 
The statistical simulations carried out by Price et al. (2011) showed that where there was an 278 
unanticipated sex difference and testing was carried out in the less sensitive sex, this would 279 
usually result in misclassification, regardless of the method used. Consequently, the new 280 
test guideline proposes that a sighting study should be performed not only to determine a 281 
suitable starting concentration for the main study but to also identify whether there is a more 282 
sensitive sex. The sighting study is not recommended if there is existing information on 283 
which to base these two decisions. Despite the earlier proposal that females should be the 284 
default sex, the more recent data that failed to show any difference, and the general view of 285 
the OECD coordinators, and their nominated inhalation experts, that males were potentially 286 
more sensitive for inhaled substances, led to the proposal that males should be used in 287 
preference.  288 
 289 
The new sighting study uses a single male and a single female at one or more of the fixed 290 
concentrations, depending on the outcome at each concentration as described by Stallard et 291 
al. (2011) (Figure 4). If there is no difference in sensitivity between the sexes, then the 292 
choice of sex for single sex studies for the FCP is irrelevant, and will not affect the 293 
classification. Since males are now the default sex, if they are the more sensitive, correct 294 
classification will still be made, since this is correctly based on the more sensitive sex. It is 295 
only if females are the more sensitive sex and this is not correctly identified, that there is 296 
potential for incorrect classification.   297 
 298 
Though the risk of a sex difference is low, the new sighting study must be robust enough 299 
despite using only one male and one female to identify the large differences in sensitivities 300 
that might risk misclassification. To demonstrate this, we have carried out statistical 301 
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calculations of the probability of choosing the most sensitive sex, with varying ratios of male 302 
and female sensitivity (i.e. LC50 values) (Figure 5). The methods are similar to those 303 
described by Stallard et al. (2011). Figure 5 shows the classification probabilities using the 304 
new sighting study for dusts and mists with a concentration-response curve slope of 4 and R 305 
(the ratio of the LC50 and TC50, the concentration expected to cause death or evident toxicity) 306 
of 5 for both sexes, assuming a sighting study starting at 0.05mg/L. The heavy solid line 307 
gives the probability of the correct classification given the LC50. The heavy dashed line gives 308 
the probability that the main study is conducted in females rather than males. 309 
 310 
The first plot of Figure 5 corresponds to the case of no difference between the sexes (i.e. 311 
males and females have identical LC50 values).  In this case, the probability of the main 312 
study being carried out in females varies around 0.25, and since there is no difference in 313 
sensitivity this will not affect the classification. The other plots show what happens with 314 
increasingly large sex differences, with the females becoming more susceptible.  In these 315 
cases the LC50 on the x-axis is that for the females, as this is the true value on which 316 
classification should be based (since females are more sensitive), and the dashed line gives 317 
the probability that the main study is conducted in the females. When the sex difference is 318 
small, there is quite a high chance of erroneously testing in the males when the females are 319 
marginally more sensitive.  For example, for a LC50 ratio 1.5 the probability of incorrectly 320 
testing in the males is more than 0.5 in many cases.  However, since the sex difference is 321 
small this is unlikely to impact the classification.  As the sex difference increases, the chance 322 
of seeing the sex difference in the sighting study and doing the main test in the females 323 
correctly also increases.  For a ratio of LC50 values of 10 or more the probability of choosing 324 
females for the main test exceeds 0.9 except for the least toxic substances, when no effects 325 
are seen in either sex even at the highest test concentration, or extremely toxic substances, 326 
when deaths are seen in both sexes at the lowest test concentration.  The probability of 327 
misclassification is higher therefore for GHS classes 3 and 4.  328 
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These simulations show that the use of a single male and a single female in the sighting 329 
study should be sufficient to identify broad differences in sensitivities.  Since the effect of sex 330 
differences is less when the concentration-response curve is steeper, these simulations 331 
represent a worst-case scenario when based on a slope of 4, as it is estimated that only 1% 332 
of substances have a concentration-response curve slope of less than this (Greiner, 2008).  333 
Again, it is important to note that sex differences are relatively uncommon and only 334 
unanticipated greater sensitivity in females is likely to influence classification. Furthermore, 335 
for many substances prior knowledge may be also available (e.g. from the oral route) which 336 
can be used to verify or indicate any suspected or apparent differences in sensitivity.   337 
For the FCP method, the purpose of the sighting study is also to identify the starting 338 
concentration for the main study where existing information is insufficient to make an 339 
informed decision. A starting concentration should be chosen that is expected to cause 340 
evident toxicity in some animals, and the use of two animals, one male and one female, 341 
should be sufficient to determine whether this estimation is too high and allow a lower dose 342 
to be used in the main study, particularly if existing data are available. The ATC method 343 
does not include a sighting study and the choice of starting concentration is based on prior 344 
knowledge or experience, or use of the suggested default starting concentrations of 10 mg/L, 345 
1 mg/L or 2500 ppm for vapours, dusts/mists and gases, respectively.  This is also an option 346 
for the FCP method, since the sighting study is not compulsory.  However, without the aid of 347 
a sighting study, it is possible that an inappropriate starting concentration may be chosen, 348 
which could result in testing at more concentrations and using more animals.  349 
4. Comparability to existing methods and retrospective analyses 350 
A number of publications have addressed the comparability of the three methods using 351 
statistical calculations or simulations to compare the classifications made by each of the 352 
three methods and the likelihood of misclassification (under or over) (Price et al. 2011; 353 
Stallard et al. 2011; Stallard et al. 2003).  The calculations described above were based on 354 
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hypothetical mortality concentration curves (with varying steepness) for a range of LC50 355 
values covering all five toxic classes to represent a wide range of hypothetical substances.  356 
These include substances that clearly fall within a specific toxic class, (i.e. LC50 within the 357 
mid-range of the class bracket) as well as those on the class border (i.e. the most or least 358 
toxic substances in each class) where there is greater potential for misclassification.  The 359 
simulations also took into account the potential for variation between the actual 360 
concentration tested and the intended fixed concentration.  For the calculations, a variation 361 
of +/- 25% was used although this is greater than that permitted in the TG (+/- 20%) so these 362 
represent worst-case examples.   363 
The statistical calculations showed that the three methods were comparable, although each 364 
of the methods did have the potential to misclassify even though the risk of this was low 365 
overall (Price et al., 2011).  If anything, the FCP tended to over-classify and the other two 366 
methods to under-classify.  The impact of misclassification (over or under) and the choice of 367 
inhalation test method may raise some diversity of opinion depending on safety, commercial 368 
and 3Rs (Replacement, Refinement and Reduction) perspectives. The tendency of the LC50 369 
and ATC methods to under-classify is more of a concern to human health than the FCP 370 
tendency for over-classification. However, it is worth highlighting that the statistical models 371 
that these conclusions were based on used a conservative ‘worst-case’ scenario, with a low 372 
concentration-response slope of four, and the potential to over-classify becomes less with a 373 
steeper concentration–response curve.  Moreover, the models used a greater than permitted 374 
variation of the actual concentration from that intended.  375 
The statistical calculations described above show that the three methods are comparable, 376 
particularly in the absence of sex differences, or where these have been taken into account 377 
with the use of the sighting study.  However, all these methods rely on the assumption of 378 
correct identification or prediction of the LC50 value and the corresponding GHS class and 379 
are not based on real data. We have therefore undertaken further analysis of the data set of 380 
178 dusts and mists to make retrospective classifications by all three methods and to 381 
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compare their performance. For each method, the classifications were established using the 382 
protocols and flow charts in their corresponding test guidelines, based on the order the 383 
studies were carried out in practice (i.e. using the default or otherwise determined starting 384 
concentration). Supplementary Data File 2 contains information on the ‘classification rules’ 385 
for each method.  For the LC50 method, rather than establish an LC50 value from the data, a 386 
flowchart method was used based on whether more or less than 50% animals died at each 387 
concentration (as in Figure 1 in Price et al. 2011). Only ‘valid’ concentrations corresponding 388 
to within ±20% of the four fixed concentrations for dusts and mists in the ATC and FCP 389 
protocols (0.05, 0.5, 1 and 5 mg/L) were included, to comply with the guidelines.  390 
Retrospective classifications could only be made for substances where all the necessary and 391 
valid concentrations were available.  For example, in the FCP method, where testing started 392 
at 1mg/L and there was no death or evident toxicity in any animal, further testing would be 393 
required at 5mg/L.  If this concentration had not been tested or fell outside of the ±20% 394 
criterion, then this substance could not be classified.  395 
Retrospective classifications were made for 77 substances via the LC50 method, 57 396 
substances via ATC, and 124 substances for FCP.  For the FCP, classifications were 397 
generally able to be made using one or two concentrations requiring five to ten animals 398 
(Table 7). For the ATC and LC50 methods, classifications were generally made after two 399 
concentrations, requiring 12 animals and 20 animals respectively.  400 
There were 42 substances for which a retrospective classification was made via all three 401 
methods (including based on females and males separately), and for 35 of these (83.3%) all 402 
classifications were in agreement (Table 8). If using the LC50 as the ‘reference’ method 403 
(though as described above there are limitations for this method and potential for 404 
misclassification), the ATC method under-classified by one class on three occasions.  For 405 
the FCP method, when conducted in males only, there was one occasion of over-406 
classification, and one of under-classification, both by one class.  When the FCP was 407 
conducted in females only, there was also one occasion of over-classification, in the 408 
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adjacent more stringent class, but three occasions of under-classification, one of these by 409 
two classes (class 4 vs. class 2).  The reasons for these differences could be because the 410 
retrospective classification method was not able to take sex differences into account, or 411 
because the LC50 value falls near a class border where there is greater potential for 412 
misclassification.  Table 9 shows that for 6 of these 7 substances there appears to be a 413 
more sensitive sex.  If for the FCP, the classification is made according to the most sensitive 414 
sex, there are fewer disagreements with the classifications from the LC50 method.  For 415 
example, instead there are now three occasions where classification made via FCP differs 416 
from LC50, and these are all over-classifications into the adjacent more stringent class.  417 
Whereas the three occasions where the ATC method differed from the LC50 method were 418 
under-classifications into the less stringent adjacent class.  This supports the conclusions 419 
from the statistical calculations that show the FCP is comparable to the existing methods if 420 
sex differences are taken into account. 421 
Often it was not possible to make a retrospective classification using all three methods (e.g. 422 
due to a missing concentration), and there are more examples of the classifications made by 423 
two of the methods.  Table 10 shows the agreement between any two of the methods. With 424 
the exception of the male and female comparisons, which had an agreement of 76.5% and 425 
87.0% for the FCP and LC50 methods respectively, there was over 90% agreement with all 426 
combinations of the other methods.  Supplementary Tables S1 -S7 compare the 427 
classifications made by each of these methods.  The difference between the male and 428 
female comparisons may reflect differences in sensitivities between sexes and the fact that 429 
for the other comparisons the same animals will have been used to make the classification, 430 
which could not be done for the male and female comparisons.  It is vital for the acceptance 431 
of the new TG that there is strong agreement between the classifications made by the FCP 432 
and the two accepted methods, irrespective of the sex used by the FCP.  433 
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However, as previously pointed out, a major difference between the three methods is the 434 
number of studies required to make a classification and consequently the numbers of 435 
animals used (Table 7).   436 
5. Summary and conclusions 437 
The new work described here strengthens and clarifies the conclusions of earlier 438 
publications on the FCP method.  In particular we have shown that evident toxicity can 439 
reliably predict death or moribund status at the next highest fixed concentration irrespective 440 
of the fold-change in concentration or the number of animals showing the sign of evident 441 
toxicity, so demonstrating the robustness of the method. 442 
As part of the OECD approval process, the simplicity of the definition of evident toxicity was 443 
questioned (i.e. that evident toxicity is said to have been reached if only one of the four signs 444 
is observed at least once in at least one animal).  However, the dataset had been 445 
extensively interrogated to look at multiple scenarios, including the effect of combinations of 446 
signs, the duration of signs, and/or the number of animals displaying the sign(s) (see 447 
sections 2.5 and 2.6 and Sewell et al., 2015).  Whilst predictivity did increase to some extent 448 
for some of these, these were associated with wider confidence intervals, since the pool of 449 
data also decreased. Clearly, if other data sets become available, it might be possible to 450 
confirm these trends more precisely. Therefore, increases in severity and/or the number of 451 
animals displaying the sign may increase confidence in the decision, but the statistical 452 
analysis of the dataset supports the simple definition regardless of any of such additional 453 
information.     454 
The change of the default sex from female to male was an unexpected outcome from the 455 
consultation with the OECD national coordinators, but there was no evidence from the 456 
analysis of Sewell et al. (2015) for a consistent bias one way or the other.  The decision 457 
therefore to adopt males as the default sex was based on the experience of the national 458 
coordinators and their nominated inhalation experts. However, since use of the less sensitive 459 
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sex could result in misclassification, it was important to establish that the proposed sighting 460 
study with one male and one female would have the power to identify the more sensitive 461 
sex, at least under those circumstances where the difference in sensitivity was large enough 462 
that it might have led to wrong classification and in the absence of existing information on 463 
sex differences. The results of the statistical analysis confirms that a sighting study with one 464 
male and one female has the power to identify the more sensitive sex. 465 
The retrospective analysis of the dataset to classify the chemicals by all three methods 466 
(LC50, ATC and FCP) was especially important in gaining acceptance of TG 433 by OECD.  467 
Agreement between the three methods is very good as only 7 out of 42 substances showed 468 
any disagreement between the three methods and then by only one class if the most 469 
sensitive sex was selected for the FCP method. All three methods have the potential to 470 
misclassify so it is important that the advantages and limitations of each test method are 471 
understood so that users can select the most appropriate test method for their needs. 472 
However in the absence of any other considerations, the FCP method is to be preferred 473 
since it offers animal welfare benefits through the avoidance of death as an endpoint, and 474 
other 3Rs benefits through the use of fewer animals and fewer studies when compared to 475 
the ATC and LC50 methods.  We hope that these factors will encourage wide uptake and use 476 
of the method in the future.  477 
We attribute the reluctance to use the equivalent method for oral toxicity studies (TG 420) to 478 
lack of guidance on evident toxicity and the absence of the detailed analyses described 479 
here, that were needed to convince the OECD national coordinators that TG 433 was fit for 480 
purpose. A similar exercise is therefore planned in collaboration with the European 481 
Partnership for Alternatives to Animal Testing to examine clinical signs observed during 482 
acute oral toxicity studies and to provide guidance that will encourage the use of TG 420.  483 
The experience of gaining acceptance of the FCP method for acute inhalation has been both 484 
positive and negative. The positive is the agreement to accept extensive retrospective 485 
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analysis as sufficient justification for a new test guideline without the need for prospective 486 
validation studies which would have required further use of animals.  This approach could no 487 
doubt be used on other occasions. The negative is the inordinately long time it has taken to 488 
get this method accepted even though the principle of evident toxicity had already been 489 
accepted by OECD, and the cumbersome process of consultation and submission which 490 
was required. Even now, the experience with the oral toxicity guideline TG 420 suggests that 491 
there will still be work needed to ensure that TG 433 becomes the preferred method for 492 
assessment of inhalation toxicity, and it is to be hoped that this will not take a further 13 493 
years.     494 
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Figure Legends 550 
Figure 1:  LC50 test (OECD test guideline 403) for dusts and mists, using example 551 
concentrations, starting at 5 mg/L (Price et al., 2010). Please note the LC50 test method does 552 
not require fixed concentrations, but specifies that 10 animals (5 males and 5 females) 553 
should be exposed at three different concentration levels. The concentration levels should 554 
be sufficiently spaced to enable construction of a mortality curve so that an estimation of the 555 
LC50 can be obtained. 556 
 557 
Figure 2:  Acute toxic class (ATC) method for dusts and mists for an example starting 558 
concentration of 5 mg/L (Price et al., 2010). Please note, the ATC method specifies that 6 559 
animals (3 males and 3 females) are tested at fixed concentrations that form the upper limit 560 
of the GHS categories. The starting concentration is either the highest concentration, or that 561 
which is expected to lead to mortality in some of the exposed animals, based on prior 562 
information. 563 
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 564 
Figure 3:  Fixed concentration procedure (FCP) method for dusts and mists for an example 565 
starting concentration of 5 mg/L (Price et al., 2010). Please note, the draft test guideline 566 
specifies that substances are tested at fixed concentrations that form the upper limit of the 567 
GHS categories. The starting concentration is chosen to be the fixed concentration level that 568 
is most likely to lead to evident toxicity but not death. 569 
 570 
Figure 4:  FCP sighting study for dusts and mists. 571 
 572 
Figure 5: Classification probabilities for the fixed concentration procedure (FCP) with the 573 
new sighting study for dusts and mists with concentration-response curve slope of 4 and R 574 
(LC50/TC50) of 5 assuming sighting study starting at 0.05 mg/L. The different plots show 575 
varying sex differences, to assess the impact of increased female sensitivity compared to 576 
male (i.e. female LC50 increasingly lower than male LC50).   The vertical dotted line in each 577 
plot indicates the classification boundary concentrations and the light solid line indicates the 578 
cumulative probabilities of classification (on left-hand axis scale) into each toxic class for 579 
LC50 values shown. The heavy solid line gives the probability of the correct classification 580 
given the LC50. The heavy dashed line gives the probability that the main study is conducted 581 
in females rather than males.  For more information on these plots please refer to Stallard et 582 
al. (2011). 583 
 584 
Supplementary data 585 
Supplementary Data File 1: Information on the predictivity and sensitivity of each of the 586 
clinical signs observed in the dataset.  587 
Supplementary Data File 2:  ‘Classification rules’ for each method.   588 
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Table 1: Comparison of LC50, ATC and FCP methods.  
Parameter LC50 (concentration 
causing 50% lethality) 
ATC  
(acute toxic class) 
FCP  
(fixed concentration procedure) 
OECD  
Test Guideline 
403 436 433  
Endpoint Death Death Evident toxicity 
Sighting study No sighting study 
required. 
No sighting study required. A sighting study may be carried out to help inform the 
starting concentration and choice of sex, if deemed 
necessary. This is not compulsory.  
 
1M+1F at one to four concentrations (usually only one 
or two concentrations required). 
 
The starting concentration should be that which is most 
expected to produce evident toxicity in some animals. 
If no prior information is available this should be 10 
mg/L, 1 mg/L or 2500 ppm for vapours, dusts/mists 
and gases, respectively.  
 
Number of 
animals 
5M+5F per study. 
Usually three studies 
required. 
Min 10 – max 40 
animals. 
3M+3F per study. 
Usually at least two studies required (12 animals), 
though classification can sometimes be made based 
on one study, if testing at the lowest or highest 
concentrations (depending on the outcome). 
Numbers of animals range from 6 to max 24 
(depending on the number of studies). An 
inappropriate starting concentration (causing too much 
or too little toxicity) may require testing at additional 
concentrations and may therefore result in higher 
numbers of animals being used.   
Where a marked sex difference is observed additional 
Single (most sensitive) sex, or males only as default. 5 
animals per study. 
Classification can often be made after a single study (5 
animals). 
Numbers of animals range from 5 to max 20 
(depending on the number of studies). Plus 2-8 in the 
sighting study (though the use of 8 animals in the 
sighting study would be very unusual, and only if the 
highest or lowest concentrations were chosen 
inappropriately as the starting concentration).  
An inappropriate starting concentration (causing too 
much or too little toxicity) may require testing at 
additional concentrations and may therefore result in 
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animals may be required. higher numbers of animals being used.  However, a 
sighting study should avoid this. 
Number of 
concentrations 
At least three 
concentrations (to 
enable production of a 
concentration-mortality 
curve and estimation of 
LC50). 
 
An ‘up and down method’ is used, requiring 1 to 4 fixed 
concentrations (based on the upper limit of the GHS 
classification system) depending on the outcome at 
each concentration. 
Generally at least two concentrations are required to 
make a classification. Sometimes a classification can 
be made based on only one study if starting at the 
highest or lowest fixed concentration, and depending 
on the outcome. 
An ‘up and down method’ is used, requiring 1 to 4 fixed 
concentrations (based on the upper limit of the GHS 
classification system) depending on the outcome at 
each concentration. 
A classification can often be made based on one study 
only. 
Starting 
concentration 
n/a   
This is not a sequential 
method.  At least three 
concentrations are 
required to enable 
production of a 
concentration-mortality 
curve and estimation of 
LC50. 
Starting concentration level should be that which is 
most likely to produce toxicity in some animals. 
 
If no prior information is available the starting 
concentration will be 10 mg/L, 1 mg/L or 2500 ppm for 
vapours, dusts/mists and gases, respectively.  
 
An inappropriate starting concentration (causing too 
much or too little toxicity) may require testing at more 
concentrations than if a more appropriate 
concentration had been chosen.   
Starting concentration level should be that which is 
most expected to produce evident toxicity in some 
animals. The sighting study may inform this choice, or 
prior information if available.  
 
If a sighting study has not been conducted or is 
inconclusive, or if no prior information is available the 
starting concentration will be 10 mg/L, 1 mg/L or 2500 
ppm for vapours, dusts/mists and gases, respectively.  
 
An inappropriate starting concentration (causing too 
much or too little toxicity) may require testing at more 
concentrations than if a more appropriate 
concentration had been chosen. The use of a sighting 
study should avoid this.  
Classification 
Method 
Based on a point 
estimate of LC50 which 
allows classification 
according to the GHS 
classification system.  
Based on an interval estimate of LC50, so that 
classification is based on the toxic class that the 
estimated LC50 falls within, using the GHS 
classification system.  
LC50 is inferred through the use of evident toxicity to 
predict death at a higher dose, and classification made 
according to the inferred LC50 using the GHS 
classification system. 
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Table 2: GHS classification system for inhalation. For the LC50 method, a point estimate of the LC50 
allows classification into the relevant GHS class according to the table.  The ATC method estimates 
which class the LC50 falls within and makes classification on that basis, whereas classifications made 
by FCP are based on the inferred LC50.  
GHS category Vapours (mg/L) Dusts and mist 
(mg/L) 
Gases (ppm) 
1 (most toxic) ≤0.5 ≤0.05 ≤100 
2 >0.5 and ≤2 >0.05 and ≤0.5 >100 and ≤500 
3 >2 and ≤10 >0.5 and ≤1 >500 and ≤2,500 
4 >10 and ≤20 >1 and ≤5 >2,500 and ≤20,000 
5 >20 >5 >20,000 
GHS, Globally Harmonised System; LC50, median concentration; ppm, parts per million. 
 
Table 3: Clinical signs indicating evident toxicity (PPV, sensitivity and specificity) 
Clinical signs PPV (95% CI) Sensitivity (95% CI) Specificity (95% CI) 
Hypoactivity 100.0 (92.4 - 100.0) 18.4 (13.6 - 24.1) 100.0 (95.2 - 100.0) 
Tremors 100.0 (68.8 - 100.0) 3.90 (1.90 - 7.20) 100.0 (95.2 - 100.0) 
Bodyweight loss 94.0 (84.6 - 98.4) 22.7 (17.4 - 28.8) 95.1 (87.2 - 98.7) 
Irregular 
respiration 
89.0 (80.9 - 94.5) 35.3 (29.0 - 42.0) 85.2 (74.7 - 92.5) 
CI, Confidence Interval; PPV, positive predictive value. 
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Table 4: Number of animals displaying a clinical sign in isolation, and the total number of animals 
displaying the sign.   
Clinical sign No. animals displaying 
sign ONLY (%) 
 
Total no. animals 
displaying the sign 
Irregular respiration 137 (42%) 325 
Body staining 27 (27%) 99 
Hypoactivity 12 (16%) 77 
Laboured respiration 12 (16%) 77 
Faeces reduced 13 (12%) 107 
Hunched posture 18 (8%) 227 
Ano-genital staining 4 (8%) 51 
Naso-ocular discharge 6 (7%) 89 
Congested respiration 4 (5%) 87 
Facial staining 3 (5%) 65 
>10% bodyweight loss 2 (2%) 93 
Noisy respiration 1 (0.4%) 267 
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Table 5: Studies where irregular respiration was observed only once in one animal at the lower 
concentration in females, with no other signs.  
Study Concentration 
tested 
Female observations Male observations 
Number of 
Deaths 
Number 
with 
evident 
toxicity 
Number of 
Deaths 
Number 
with 
evident 
toxicity 
1 0.05 mg/L 0 1 0 4 
0.5 mg/L 5 - 3 2 
2 mg/L 5 - 5 0 
2 0.06 mg/L 0 1 0 5 
0.5 mg/L 2 3 3 2 
2 mg/L 4 1 5 - 
3 0.5 mg/L 0 1 0 4 
2 mg/L 2 3 2 3 
4 0.05 mg/L 0 1 0 2 
0.2 mg/L 5 - 5 - 
2 mg/L 5 - 5 - 
5 mg/L 5 - 5 - 
5 0.06 mg/L 0 1 n/a n/a 
0.5 mg/L 2 3 0 5 
2 mg/L 5 - 5 0 
 
 
Table 6:  PPV (95% confidence interval) for highly predictive signs with 2, 5 or 10-fold concentration 
change between the lower and higher concentration. 
Clinical sign ≥2-fold   (95% CI) ≥5-fold  (95% CI) ≥10-fold (95% CI) 
Tremors 100.0 (68.8 - 100.0) 100.0 (5.0 - 100.0) 100.0  (5.0 - 100.0) 
Hypoactivity 100.0 (92.0 - 100.0) 100.0 (47.3 - 100.0) 100.0  (47.3 - 100.0) 
>10% bodyweight loss 91.7 (79.0 - 97.8) 85.7 (47.0 - 99.3) 100.0  (36.8 - 100.0) 
Irregular respiration 89.0 (80.9 - 94.5) 95.8 (81.2 - 99.8) 100.0  (86.1 - 100.0) 
Body staining 88.5 (71.8 -  97.0) 100.0 (60.7 - 100.0) 100.0  (22.4 - 100.0) 
Ano-genital staining 86.4 (67.3 - 96.4) 0.0 (0.0 - 95.0) 100.0  (5.0 - 100.0) 
Faeces reduced 85.3 (70.4 - 94.4) 100.0 (47.3 - 100.0) 100.0  (47.3 - 100.0) 
Naso-ocular discharge 84.2 (70.1 - 93.3) 100.0 (74.1 - 100.0) 100.0  (65.2 - 100.0) 
Noisy respiration 80.5 (70.9 - 88.0) 94.1 (74.3 - 99.7) 100.0  (68.8 - 100.0) 
Hunched posture 78.0 (65.0 – 87.8) 87.5 (64.5 - 97.8) 100.0  (54.9 - 100.0) 
Gasping 76.5 (52.5 – 92.0) 100.0 (22.4 - 100.0) 100.0  (22.4 - 100.0) 
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Table 7: Number of studies required to make a classification, and the associated number of animals. 
No. studies 
to make a 
classification 
FCP ATC LC50 
No. 
animals 
involved 
No. studies No. 
animals 
involved 
No. 
studies 
No. 
animals 
involved 
No. 
Studies FCP-F FCP-M 
1 study  5  54  64 6  18 10  32 
2 studies  10  46  41 12  37  20  41 
3 studies  15  1  3 18  2 30  3 
4 studies  20  0  1 24 0 40  1 
 
 
Table 8: Classifications made by all three methods, showing the number of substances classified into 
each class and the number of substances where there was a disagreement between the three 
methods (which is expanded on in Table 9). 
Classification No. substances 
Class 1 1 
Class 2 11 
Class 3 3 
Class 4 14 
Class 5 6 
Disagreements 7 
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Table 9:  Substances where there were differences in retrospective classifications made via the LC50, ATC and FCP methods.  FCP retrospective 
classifications were made for both females (F) and males (M) only.  For each substance the concentrations tested, the number of deaths and/or animals with 
evident toxicity are indicated.   
Substance Concentrations 
tested 
No. deaths No. evident 
toxicity 
Classification  
F M F M LC50 ATC FCP(F) FCP(M)  
1 0.5mg/L 0 0 0 0 3 4 3 4   1 mg/L 4 1 1 0 
2 1 mg/L 0 0 4 4 5 5 4 5   5 mg/L 2 1 3 4 
3 1 mg/L – males - 0 - 0 5 5 5 4   5 mg/L 0 2 5 3 
4 1 mg/L – males - 0 - 5 4 5 5 4   5 mg/L 0 3 5 2 
5 0.05 mg/L 0 0 0 0 
2 2 4 2   0.5 mg/L  3 4 0 0 
1 mg/L 1 4 2 0 
6 1 mg/L 0 0 0 0 5 5 4 5   5 mg/L 2 0 3 5 
7 0.5 mg/L 0 0 0 0 
3 4 4 3   1 mg/L 1 3 4 2 
5 mg/L 5 5 - - 
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Table 10: Differences in classifications between the three methods, showing the numbers of 
substances for which pairwise comparisons were made, and the number for which there was 
agreement between the two methods.  
Comparison No. classified No. substances in 
agreement % agreement 
FCP-M  vs. FCP-F 85 65 76.5% 
LC50-M vs. LC50-F 46 40 87.0% 
ATC vs. FCP-F  46 42 91.3% 
LC50 vs. FCP-F 43 40 93.0% 
LC50 vs. FCP-M 44 41 93.2% 
ATC  vs. FCP-M 51 48 94.1% 
LC50 vs. ATC 46 44 95.7% 
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Highlights: 
The FCP for acute inhalation toxicity has been accepted by OECD as TG433. 
TG433 uses evident toxicity while other approved methods use lethality. 
A sighting study with 1 M and 1 F animal reliably identifies the more sensitive sex. 
The three methods (LC50, ATC, FCP) showed good agreement in a retrospective analysis.  
 
